← Eichor
Study identifier: NCT07145489 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Infrared Photobiomodulation in Humans With Epilepsy

Condition: Drug Resistant Epilepsy  ·  Sponsor: Beth Israel Deaconess Medical Center

PhaseNA
Planned participants13
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Daniel Goldenholz, MD, PhD  ·  617-632-8930  ·  daniel.goldenholz@bidmc.harvard.edu

Daniel Goldenholz, MD PhD  ·  617-632-8930  ·  daniel.goldenholz@bidmc.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

BIDMCBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07145489